XNASMREO
Market cap108mUSD
Dec 31, Last price
3.50USD
1D
-0.57%
1Q
-18.41%
IPO
-40.88%
Name
Mereo Biopharma Group PLC
Chart & Performance
P/E
—
P/S
43.26
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
56.10%
Rev. gr., 5y
%
Revenues
10m
+563.57%
Net income
-29m
L-13.83%
CFO
-21m
L-45.56%
Earnings
May 23, 2025
Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 10,000 563.57% | 1,507 -95.87% | |||||||
Cost of revenue | 38,416 | 45,441 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (28,416) | (43,934) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (532) | (1,897) | |||||||
Tax Rate | |||||||||
NOPAT | (27,884) | (42,037) | |||||||
Net income | (29,466) -13.83% | (34,196) -368.73% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 11,605 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 652 | 11,551 | |||||||
Long-term debt | 6,858 | 2,910 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,176 | 311 | |||||||
Net debt | (49,911) | (41,873) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (21,132) | (38,820) | |||||||
CAPEX | (10) | ||||||||
Cash from investing activities | (419) | 1,497 | |||||||
Cash from financing activities | 7,973 | (784) | |||||||
FCF | (27,703) | (41,338) | |||||||
| Balance | |||||||||
Cash | 57,421 | 56,334 | |||||||
Long term investments | |||||||||
Excess cash | 56,921 | 56,259 | |||||||
Stockholders' equity | (434,340) | (191,377) | |||||||
Invested Capital | 492,005 | 266,162 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 659,454 | 603,196 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (27,355) | (43,207) | |||||||
EV/EBITDA | |||||||||
Interest | 2,881 | 3,361 | |||||||
Interest/NOPBT | |||||||||